by: Uniradio Informa – 29 March 2020, 07:01 am
UNITED STATES.- Abbott Laboratories is presenting a test of coronavirus that can determine if someone is infected in as little as five minutes, and it’s so small and portable that can be used in almost any care environment.
The medical device manufacturer plans to supply 50,000 tests per day from 1 April, said John Frels, vice-president of research and development, Abbott Diagnostics. The molecular test looks for fragments of the genome of the coronavirus, that can be quickly detected when they are present in high levels. A thorough search to rule out definitely an infection can take up to 13 minutes, he said.
Abbott received an authorization of emergency use of the Food and Drug Administration de EE. UU. “For use of approved laboratories and patient care settings,” the company said on Friday.
The united states has struggled to provide enough evidence to detect the virus even when the outbreak threatens to overwhelm the hospitals in New York, California, Washington and other regions. After restricting initial testing to high-risk individuals, and the problems with a test designed by the Centers for Control and Prevention of Diseases, the regulators of EE. UU. Have hastened to the diagnoses made by the main companies of commercial tests in the world.
“This really will provide a great opportunity for caregivers first-line, those who have to diagnose many infections, to close the gap with our tests,” said Frels. “A clinic may change this result quickly, while the patient is waiting”.
The technology is based on the platform Abbott’s ID Now, with headquarters in Illinois, the test of point-of-care most common currently available in the united states. UU., With over 18,000 units spread across the country. It is widely used to detect influenza, strep throat, and respiratory syncytial virus, a common error that causes symptoms similar to a cold.
The test begins with taking a swab of the nose or the back of the throat, then to mix it with a chemical solution that breaks down the virus and releases its RNA. The mixture is inserted into a system ID Now, a small box of little less than 7 pounds that has the technology to identify and amplify selected sequences of the genome of the coronavirus and ignoring the contamination of other viruses.
The equipment can be set up almost anywhere, but the company is working with its customers and the management Trump to ensure that the first cartridges used for the testing are sent to where they are needed most. Are directed to emergency rooms of hospitals, clinics, urgent care, and physicians ‘ offices.
Last week, the system m2000 RealTime Abbott won approval from the Food and Drug Administration of the united States for use in hospitals and laboratories at the molecular level to diagnose infection. This system can perform more tests daily, up to 1 million per week, but it takes more time to get the results. Abbott plans to provide at least 5 million tests per month between the two systems.
Other companies are also implementing test systems faster. Henry Schein Inc. he said Thursday that his antibody test at the point of care, looking for evidence that a person’s immune system has already fought off the infection, was available. The blood test can be administered at the point of care and provides results in approximately 15 minutes, although it can not be used to definitively diagnose a current infection.